76 related articles for article (PubMed ID: 16739351)
1. Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma.
Ogo Y; Nio Y; Yano S; Toga T; Koike M; Hashimoto K; Itakura M; Maruyama R
Anticancer Res; 2006; 26(1B):763-70. PubMed ID: 16739351
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
Shafizadeh N; Grenert JP; Sahai V; Kakar S
Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer.
Kim WB; Han HJ; Lee HJ; Park SS; Song TJ; Kim HK; Suh SO; Kim YC; Choi SY
Ann Surg Oncol; 2009 Jan; 16(1):23-34. PubMed ID: 18979138
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of fascin expression in extrahepatic bile duct carcinomas.
Won KY; Kim GY; Lim SJ; Park YK; Kim YW
Pathol Res Pract; 2009; 205(11):742-8. PubMed ID: 19556073
[TBL] [Abstract][Full Text] [Related]
6. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance.
Zheng J; Zhu YM
Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):412-5. PubMed ID: 17690040
[TBL] [Abstract][Full Text] [Related]
8. Akt expression may predict favorable prognosis in cholangiocarcinoma.
Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
[TBL] [Abstract][Full Text] [Related]
9. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
10. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma.
Zhou L; He XD; Cui QC; Zhou WX; Qu Q; Zhou RL; Rui JA; Yu JC
Cancer Lett; 2008 Jun; 264(2):209-17. PubMed ID: 18334282
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-I overexpression is a favourable prognostic factor for patients with extrahepatic bile duct carcinoma.
Murakami S; Miyamoto M; Hida Y; Cho Y; Fukunaga A; Oshikiri T; Kato K; Kurokawa T; Suzuoki M; Nakakubo Y; Hiraoka K; Itoh T; Shinohara T; Morikawa T; Okushiba O; Kondo S; Katoh H
Br J Cancer; 2003 Apr; 88(8):1234-8. PubMed ID: 12737162
[TBL] [Abstract][Full Text] [Related]
13. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma.
Tamada S; Shibahara H; Higashi M; Goto M; Batra SK; Imai K; Yonezawa S
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4257-64. PubMed ID: 16857800
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
Williams MD; Roberts D; Blumenschein GR; Temam S; Kies MS; Rosenthal DI; Weber RS; El-Naggar AK
Am J Surg Pathol; 2007 Nov; 31(11):1645-52. PubMed ID: 18059220
[TBL] [Abstract][Full Text] [Related]
15. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma.
Möbius C; Demuth C; Aigner T; Wiedmann M; Wittekind C; Mössner J; Hauss J; Witzigmann H
Eur J Surg Oncol; 2007 Oct; 33(8):1025-9. PubMed ID: 17400419
[TBL] [Abstract][Full Text] [Related]
17. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of extrahepatic bile duct resection for advanced gallbladder cancer.
Sakamoto Y; Kosuge T; Shimada K; Sano T; Hibi T; Yamamoto J; Takayama T; Makuuchi M
J Surg Oncol; 2006 Sep; 94(4):298-306. PubMed ID: 16917876
[TBL] [Abstract][Full Text] [Related]
19. HER-family gene amplification and expression in resected pancreatic cancer.
te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
[TBL] [Abstract][Full Text] [Related]
20. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
